NCT01726166

Brief Summary

Urinary tract infection (UTI) is relatively common in infants, with an occurence rate of up to 10%. Analysis of collected urine for the presence of bacteria or fungus is the only way to make a certain UTI diagnosis. Sterile collection of urine can be achieved in newborn infants by urinary catheterization (UC) where a catheter is passed through the urethra into the bladder, suprapubic aspiration (SPA) where a needle is inserted into the bladder through the abdominal wall, or 'clean catch' where urine is collected into a sterile bottle as the baby urinates during preparation for UC. The main advantage of SPA is that it bypasses the bacteria that normally resides in the urethral opening, thus minimizing the risk of contamination. Some studies have suggested that SPA is better than UC for collecting urine in a sterile fashion in the neonate due to the difficulty of doing sterile UC in small infants resulting in more contaminated samples (also called a false-positive urine culture); there is still no clear best choice. UC is commonly used in many Neonatal Intensive Care Units (NICU) as it is considered less invasive, can be done by the nursing staff, and generally has a higher chance of obtaining urine. SPA is a simple and safe alternative and, although it may be more painful than UC, it is performed more quickly. The reported success rate for SPA is variable, but is greatly increased when an ultrasound confirms urine in the bladder. The question remains: what is the best method for sterile collection of urine in neonates? In this study, the investigators will try to answer this question by collecting urine from neonates using either ultrasound guided SPA or UC and then comparing the contamination rates between these two methods. The investigators hypothesize that SPA will result in less contamination of urine samples. The investigators also hypothesize that there will be more success in obtaining an adequate urine sample (0.5 ml) by SPA, and that there will be no difference in associated complication rates between SPA and UC.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
49

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2013

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 7, 2012

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 14, 2012

Completed
5 months until next milestone

Study Start

First participant enrolled

April 1, 2013

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2016

Completed
Last Updated

January 22, 2020

Status Verified

January 1, 2020

Enrollment Period

3.1 years

First QC Date

November 7, 2012

Last Update Submit

January 21, 2020

Conditions

Keywords

Infantcontamination ratesurinary catheterizationsuprapubic aspiration

Outcome Measures

Primary Outcomes (1)

  • Number of contaminated urine samples per SPA and UC

    For SPA samples, urine contamination will be defined as the growth of two or more micro-organisms (any number of colonies per each microorganism) or the growth of Candida species plus growth of any other microorganism. For UC samples, urine contamination will be defined as the growth of two or more micro-organisms (any number of colonies per each microorganism) or any growth \<10\^4 colony forming unit(CFU)/ml or the growth of Candida species plus growth of any other microorganism. The different cut-off used for contamination between UC and SPA samples stems from the fact that the UC procedure is not sterile in the neonatal population. Note that a bacterial load of \<10\^3 CFU/mL (e.g. 10\^1 or 10\^2 CFU/mL) does not grow in the media of either laboratory where our study samples are being cultured. Further sensitivity analyses will be performed on this outcome measure.

    up to 2 years

Secondary Outcomes (5)

  • Success rates of obtaining urine by SPA versus UC

    up to 2 years

  • Time to perform the respective procedures

    up to 2 years

  • Complication rates of SPA versus UC

    up to 2 years

  • Contamination rates of SPA versus UC (excluding clean catch urine)

    up to 2 years

  • Number of attempts per procedure

    up to 2 years

Study Arms (2)

Suprapubic Aspiration

ACTIVE COMPARATOR

A trained physician or neonatal nurse practitioner utilizing U/S guidance at the bedside will perform the SPA. An U/S machine is readily available for use in each NICU.

Procedure: Suprapubic Aspiration

Urinary Catheterization

ACTIVE COMPARATOR

The infants will have the procedure done by NICU nurses who have been trained in performing this procedure. If the randomly assigned infant passes urine spontaneously during a UC attempt after complete perineal cleansing and the urine is collected as a "clean catch" sample, then this infant will be analysed in the assigned group (intention to treat).

Procedure: Urinary Catheterization

Interventions

Pain management will be performed as per our NICU protocols by administering 24% sucrose prior to both procedures to ensure adequate pain control. Additional or different analgesia may be used depending on the patient's specific clinical situation. We will use a chlorhexidine 0.05% with no cetrimide solution as the cleaning solution.

Suprapubic Aspiration

Pain management will be performed as per our NICU protocols by administering 24% sucrose prior to both procedures to ensure adequate pain control. Additional or different analgesia may be used depending on the patient's specific clinical situation. We will use a chlorhexidine 0.05% with no cetrimide solution as the cleaning solution.

Urinary Catheterization

Eligibility Criteria

Age72 Hours - 12 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may not qualify if:

  • Antenatal detection or suspicion of genitourinary anomaly including: ambiguous genitalia, hypospadias, posterior urethral valve, anal atresia, exstrophy-epispadias complex, and oligohydramnios secondary to probable genitourinary anomaly(e.g. renal agenesis, multicystic kidney disease)
  • Antenatal hydrops
  • Antenatally detected abdominal wall defect or abdominal masses
  • Antenatally detected grossly dilated bowel loops
  • Congenital abdominal skin lesion over the SPA puncture site
  • All infants who are greater than 72 hours of age, who are being investigated for a possible UTI, and have been consented will be eligible for randomization
  • Oliguria (\<0.5 cc/kg/hr) or anuria over the 8 hours prior to attempted urine collection
  • Skin infection over the SPA puncture site
  • Distension or enlargement of abdominal viscera (e.g. grossly dilated loops of bowel or massive organomegaly)
  • Active Necrotizing enterocolitis (Bell stage II or more)
  • Uncorrected thrombocytopenia (platelets \< 50 x 10 6) or bleeding diathesis
  • Post-abdominal surgery
  • Large inguinal hernia
  • Current pre-existing indwelling catheter

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Children's Hospital of Eastern Ontario

Ottawa, Ontario, K1H 8L1, Canada

Location

The Ottawa Hospital - General campus

Ottawa, Ontario, K1H 8L6, K1H 8L6, Canada

Location

MeSH Terms

Interventions

Urinary Catheterization

Intervention Hierarchy (Ancestors)

Diagnostic Techniques, UrologicalDiagnostic Techniques and ProceduresDiagnosisCatheterizationTherapeuticsInvestigative Techniques

Study Officials

  • Gregory P Moore, MD

    Children's Hospital of Eastern Ontario; Ottawa Hospital; University of Ottawa

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor, Neonatologist

Study Record Dates

First Submitted

November 7, 2012

First Posted

November 14, 2012

Study Start

April 1, 2013

Primary Completion

May 1, 2016

Study Completion

May 1, 2016

Last Updated

January 22, 2020

Record last verified: 2020-01

Data Sharing

IPD Sharing
Will not share

Locations